Paraneoplastic Ma Antigen–Like 1 as a Potential Prognostic Biomarker in Human Pancreatic Ductal Adenocarcinoma
Authors:
- Anna KakehashiAKAnna Kakehashi
- Kenichi WakasaKWKenichi Wakasa
- Min WeiMWMin Wei
- Shotaro YamanoSYShotaro Yamano
- Naomi IshiiNINaomi Ishii
- Masahiko OhsawaMOMasahiko Ohsawa
- Hideki WanibuchiHWHideki Wanibuchi
- 1 January 2015
- journal article
- Published by Wolters Kluwer Health in Pancreas
- Vol. 44 (1) , 106-115
Abstract
The present study aimed to identify novel useful clinical biomarker at early stages and to elucidate the molecular background of carcinogenesis in human pancreatic ductal adenocarcinomas (PDACs). Proteomes of dissected PDACs and adjacent nontumor pancreatic tissues from formalin-fixed and paraffin-embedded sections from 10 patients were analyzed using QSTAR Elite liquid chromatography-tandem mass spectrometry, ProteinPilot Software, and Ingenuity Pathway Analysis. Expression of potential biomarker candidates was validated immunohistochemically in 50 PDAC patients, followed by survival analyses and statistical comparison of protein expression with clinicopathologic variables. Eight hundred five proteins displaying significant quantitative changes were identified in human PDACs by liquid chromatography-tandem mass spectrometry. Based on altered expression of downstream molecules, Ingenuity Pathway Analysis predicted up-regulation and/or activation of nuclear factor β-catenin, SOX11, enolase 1, NFE2L2, SP1, SMAD1, SMAD2, SMAD3, SMAD4, HIF-1, and others. From proteome analysis, paraneoplastic Ma antigen-like 1 was selected as a potential biomarker of human PDAC. Furthermore, paraneoplastic neuronal Ma antigen-like 1 immunohistochemical evaluation in 50 PDAC patients revealed that its positive expression was significantly associated with the better overall survival (log-rank test; P = 0.009) and histological differentiation of PDACs (well, moderate, and poor; P = 0.027) as compared with patients with negative expression. Paraneoplastic Ma antigen-like 1 is suggested as a novel potential clinically useful prognostic biomarker for patients with PDAC.Keywords
This publication has 35 references indexed in Scilit:
- Complexin-2 (CPLX2) as a potential prognostic biomarker in human lung high grade neuroendocrine tumorsCancer Biomarkers, 2013
- Validation of a robust proteomic analysis carried out on formalin‐fixed paraffin‐embedded tissues of the pancreas obtained from mouse and humanProteomics, 2012
- Mitochondrial Prohibitins and Septin 9 Are Implicated in the Onset of Rat HepatocarcinogenesisToxicological Sciences, 2010
- iTRAQ-Multidimensional Liquid Chromatography and Tandem Mass Spectrometry-Based Identification of Potential Biomarkers of Oral Epithelial Dysplasia and Novel Networks between Inflammation and PremalignancyJournal of Proteome Research, 2008
- Core Signaling Pathways in Human Pancreatic Cancers Revealed by Global Genomic AnalysesScience, 2008
- iTRAQ Experimental Design for Plasma Biomarker DiscoveryJournal of Proteome Research, 2008
- Endometrial Carcinoma Biomarker Discovery and Verification Using Differentially Tagged Clinical Samples with Multidimensional Liquid Chromatography and Tandem Mass SpectrometryMolecular & Cellular Proteomics, 2007
- Verification of Endometrial Tissue Biomarkers Previously Discovered Using Mass Spectrometry-Based Proteomics by Means of Immunohistochemistry in a Tissue Microarray FormatJournal of Proteome Research, 2007
- A perspective on the use of iTRAQTM reagent technology for protein complex and profiling studiesJournal of Experimental Botany, 2006
- Protein Expression Profiles in Pancreatic Adenocarcinoma Compared with Normal Pancreatic Tissue and Tissue Affected by Pancreatitis as Detected by Two-Dimensional Gel Electrophoresis and Mass SpectrometryCancer Research, 2004